BRCA1 Mutations May Raise Risk of Serous and Serous-Like Uterine Cancer

This article originally appeared here.
<i>BRCA1</i> Mutations May Raise Risk of Serous/Serous-Like Uterine CA
BRCA1 Mutations May Raise Risk of Serous/Serous-Like Uterine CA

THURSDAY, June 30, 2016 (HealthDay News) -- Women with BRCA mutations undergoing risk-reducing salpingo-oophorectomy (RRSO) do not have increased risk for uterine cancer, but the risk of serous/serous-like endometrial carcinoma is increased for BRCA1+ women, according to a study published online June 30 in JAMA Oncology.

Catherine A. Shu, M.D., from the Columbia University Medical Center in New York City, and colleagues examined the risk for uterine cancer and distribution of specific histologic subtypes in 1,083 women with a BRCA1 or BRCA2 mutation who underwent RRSO without hysterectomy. Overall, 627, 453, and three women were BRCA1+, BRCA2+, and both.

The researchers identified eight incident uterine cancers (4.3 expected; observed to expected [O:E] ratio, 1.9 [95 percent confidence interval (CI), 0.8 to 3.7; P = 0.09]). After stratifying by subtype there was no increased risk for endometrioid endometrial carcinoma or sarcoma. At 7.2 to 12.9 years after RRSO there were five serous and/or serous-like endometrial carcinomas (BRCA1: 0.18 expected; O:E, 22.2 [95 percent CI, 6.1 to 56.9]; BRCA2: 0.16 expected; O:E, 6.4 [95 percent CI, 0.2 to 35.5]). In all three available serous/serous-like BRCA1+ tumors there was loss of the wild-type BRCA1 gene and/or protein expression.

"This risk should be considered when discussing the advantages and risks of hysterectomy at the time of RRSO in BRCA1+ women," the authors write.

One author disclosed financial ties to the publishing and biotechnology industries.

Full Text

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs